Harmonization, biomarkers, disease risk index

摘要

In this issue of Blood, Qayed et al(1) describe the development and validation of a disease risk index (DRI) to better predict (leukemia-free) survival and to stratify pediatric acute leukemia patients undergoing allogeneic hematopoietic cell transplantation (HCT). This desperately needed risk stratification is based on disease status (including minimal residual disease), age, and cytogenetics prior to HCT.